Ontario Institute for Cancer Research and Centre for Drug Research and Development announces call for pre-proposals for early-stage research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT and the Ontario Institute for Cancer Research announced a call for pre-proposals from Canadian academic investigators focused on early-stage technologies.

The two organizations are looking to collaborate on projects that will advance the preclinical development of targeted therapeutics or approaches including small molecules, biologics and cell-based therapies.

Unlike traditional grants, CDRD and OICR will work in partnership with academic investigators to develop collaborative project plans addressing the steps required to advance cancer therapies from the lab to the clinic. Projects will be milestone-driven with clear go/no-go decision points with budgets depending on the scope of the project.

More information on the program can be found on the CDRD website.

YOU MAY BE INTERESTED IN

Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019). 
March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login